WTA Mandates Genetic Testing for Women's Tennis Tour Participation
The Women's Tennis Association (WTA) has announced new participation rules requiring all female players to undergo a one-time genetic test for the SRY gene, which is located on the Y chromosome and determines male sexual characteristics. The policy takes effect immediately and applies to all players on the women's tour. The WTA acknowledged the sensitivity of the issue but stated it is committed to treating all players with dignity. The move follows similar policies in athletics and boxing, and was prompted by the controversy surrounding women's boxing at the 2024 Paris Olympics, where athletes Imane Khelif and Lin Yu-ting were allowed to compete despite being excluded from previous world championships due to unspecified gender tests. Previously, the WTA allowed transgender women to compete if they identified as female and maintained reduced testosterone levels for two years. Currently, no transgender women are known to be active on the WTA tour.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection